Drug Type Fusion protein |
Synonyms GI 102, GI102 |
Target |
Mechanism CD80 modulators(Cluster of differentiation 80 modulators), IL-2Rβ inhibitors(Interleukin-2 receptor beta chain inhibitors), IL-2Rγ inhibitors(Interleukin-2 receptor subunit gamma inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 30 May 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | 30 May 2023 | |
Colorectal Cancer | Phase 2 | US | 30 May 2023 | |
Colorectal Cancer | Phase 2 | KR | 30 May 2023 | |
Hepatocellular Carcinoma | Phase 2 | US | 30 May 2023 | |
Hepatocellular Carcinoma | Phase 2 | KR | 30 May 2023 | |
HER2-negative breast cancer | Phase 2 | US | 30 May 2023 | |
HER2-negative breast cancer | Phase 2 | KR | 30 May 2023 | |
Ichthyosis, X-Linked | Phase 2 | US | 30 May 2023 | |
Ichthyosis, X-Linked | Phase 2 | KR | 30 May 2023 |
NCT05824975 (ASCO2024) Manual | Phase 1/2 | 32 | GI-102 (CD80-IL2v3) 0.24 mg/kg | bkrebdoddq(zsgofekrrt) = The most common ( ≥ 10%) were pyrexia [43.8%] and chills [34.4%]. llfvwshovf (eurqjnjqil ) View more | Positive | 24 May 2024 |